![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessGlucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association
Non-ER nuclear receptor activity can alter estrogen receptor (ER) chromatin association and resultant ER-mediated transcription. Consistent with GR modulation of ER activity, high tumor glucocorticoid receptor...
-
Article
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis.
-
Article
Open AccessAdjuvant ovarian function suppression and cognitive function in women with breast cancer
To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer.
-
Article
Open AccessCircadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion
Varying the rate of continuous intravenous infusions of 5-fluorouracil (5FU) chemotherapy over a 24-hour period has been reported to improve patient outcomes. It has been hypothesized that circadian variation ...
-
Article
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
Etoposide is a widely used cytotoxic drug that is commercially available in both intravenous and oral formulations. High interpatient pharmacokinetic variability has been associated with oral etoposide adminis...
-
Article
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer
Carboxyamidotriazole (CAI) is a novel antineoplastic agent in clinical development with limited oral bioavailability. In vitro, ketoconazole has been demonstrated to inhibit CYP3A4-mediated metabolism of CAI. ...
-
Article
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment
Abstract
-
Article
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil
Aims: To determine the effect of food on the pharmacokinetics of 5-fluoruracil (5-FU) taken orally with eniluracil and to compare the performance of different pharmacokinetic analysis methods in the detection a p...
-
Article
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations
In previous phase I reports of short bolus infusion of rhizoxin, problems in assay sensitivity prevented the description of pharmacokinetic-pharmacodynamic relationships, and a pharmacologically guided approa...
-
Article
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days
Purpose: To determine the feasibility, maximal tolerated doses, and response rates for a combined regimen of the platinum and 5-fluorouracil oral analogues bis-acetato-ammine-dichloro-cyclohexyl-amine platinum(I...
-
Article
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)
Purpose: 9-Aminocamptothecin (9-AC) is a topoisomerase I inhibitor with high antitumor activity but poor solubility in conventional vehicles. The purpose of this study was to evaluate the toxicities and pharmaco...
-
Article
Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein
We evaluated the multidrug resistance (MDR)-modulating effects of progesterone (PRG) and an orally active, structurally related compound, megestrol acetate (MA), in several MDR human cell lines. At 100 μm, both s...
-
Article
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis
We conducted a double-blind, randomized crossover study to compare the toxicity and antiemetic efficacy of the 5-hydroxytryptamine3 receptor antagonist batanopride with that of metoclopramide in 21 chemotherapy-n...